Lucie Ellis - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Lucie Ellis's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Lucie Ellis

Lucie Ellis

Verified

Executive Editor, In Vivo

Biography

Lucie joined the team in 2012 and is based in the UK. In her current role she covers news reporting, data visualisation projects for the Scrip website and handling of the weekly print issue. As a reporter Lucie covers a range of global news including: people and appointments; corporate financings and M&A activities; R&D news; and digital/social media development in the industry.

Final Covers

lifestyleHealth wellbeing

Doesn’t Cover

anything progressive or woke

Journalist Type

-

Seniority Positions

Industries

Medium Formats

-

Content

Total articles 608

  • Deals Shaping Medtech And Diagnostics, September 2021

    By Lucie Ellis Verified| Medtech Insight Verified In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment - In Vitro Diagnostics, Medical Devices and Pharmaceuticals - and then categorized by type - Acquisition, Alliance, or Financing. This month's column covers deals announced in September 2021. Data provided by Biomedtracker. A selection of articles you might have missed from September 2021, including exclusive interviews and a look at pharma marketing trends in 2021.

    By Lucie Ellis Verified · Medtech Insight

    Oct. 14, 2021

  • 2020 Vision For Biopharma

    By Lucie Ellis Verified| pharmaintelligence.informa.com@ ASK THE ANALYST Email Print Bookmark Welcome To The New Roaring Twenties 10 Dec 2019 Analysis Executive Summary Crystal ball gazing is a tricky, sometimes futile, endeavor.

    By Lucie Ellis Verified · pharmaintelligence.informa.com

    Dec. 10, 2019

  • Accessing CAR-T Therapies

    By Lucie Ellis Verified, William Masters| pharmaintelligence.informa.com@ ASK THE ANALYST Email Print Bookmark 26 Nov 2019 Analysis Executive Summary Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies.

    By Lucie Ellis Verified, William Masters · pharmaintelligence.informa.com

    Nov. 26, 2019

As seen in

Company Info

In Vivo

United Kingdom, United Kingdom